ASCO 2023 | KEYNOTE-966: pembrolizumab + gem/cis vs gemc/cis alone in advanced biliary tract cancer

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, provides an overview of the Phase III KEYNOTE-966 (NCT04003636) trial of pembrolizumab plus gemcitabine and cisplatin versus placebo plus gem/cis for advanced biliary tract cancer (BTC). In this randomized, double-blind, Phase III trial, pembrolizumab plus gemcitabine gem/cis significantly improved overall-survival (OS) versus placebo plus gem/cis and had an expected and manageable safety profile as first-line therapy for unresectable locally advanced or metastatic BTC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.